Skip to content
value.today

Capital Rx, Inc.

Formerly Capital RX LLC

Total raised
$500 M
6 rounds on record
Latest round
$231 M
Aug 2025
First round on record
Jul 2019
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Capital Rx, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2025$231 MNo. 6$50 to $250 million

Capital Rx, Inc.: Raise no. 6, Aug 2025

Investors in this round

8 investors had bought by the notice of Sep 26, 2025: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$231 M of $233 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. J. Loiacono · Executive Officer, Director
  • Daniel J. Delmastro · Director
  • Holly J. Maloney · Director
  • Jared J. Kesselheim · Director
  • Kevin J. Hill · Director
  • Lenard J. Marcus · Director
  • Mark J. Kandrysawtz · Director
  • Mostafa J. Kamal · Director
  • Robert J. Mittendorff · Director
  • Ryan J. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by A.J. Loiacono, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 26, 2025. Read the notice at the SEC.

equitySEC
Mar 2024$115 MNo. 5$50 to $250 million

Capital Rx, Inc.: Raise no. 5, Mar 2024

Investors in this round

1 investor had bought by the notice of Mar 22, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$115 M of $313 M offered; $198 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. J. Loiacono · Director, Executive Officer
  • Daniel J. Delmastro · Director
  • Feby J. Abraham · Director
  • Jared J. Kesselheim · Director
  • Kevin J. Hill · Director
  • Lenard J. Marcus · Director
  • Robert J. Mittendorff · Director
  • Ryan J. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by A.J. Loiacono, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 22, 2024. Read the notice at the SEC.

equity, optionsSEC
May 2022$106 MNo. 4$50 to $250 million

Capital Rx, Inc.: Raise no. 4, May 2022

Investors in this round

9 investors had bought by the notice of Jun 13, 2022: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$106 M of $106 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. J. Loiacono · Executive Officer, Director
  • Joseph J. Alexander · Executive Officer
  • Laleh J. Alemzadeh · Executive Officer · Secretary
  • Jared J. Kesselheim · Director
  • Kevin J. Hill · Director
  • Lenard J. Marcus · Director
  • Robert J. Mittendorff · Director · Appointed 5/27/2022
  • Ryan J. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by A.J. Loiacono, Ceo. Source: SEC Form D, newest notice filed Jun 13, 2022. Read the notice at the SEC.

equitySEC
Apr 2021$3 MNo. 3$2 to $10 million

Capital Rx, Inc.: Raise no. 3, Apr 2021

Investors in this round

4 investors had bought by the notice of Jul 14, 2021: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. J. Loiacono · Executive Officer, Director
  • Joseph J. Alexander · Executive Officer, Director
  • Laleh J. Alemzadeh · Executive Officer · Secretary
  • Jared J. Kesselheim · Director
  • Kevin J. Hill · Director
  • Lenard J. Marcus · Director
  • Ryan J. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by A.J. Loiacono, Ceo. Source: SEC Form D, newest notice filed Jul 14, 2021. Read the notice at the SEC.

optionsSEC
Dec 2020$32 MNo. 2$10 to $50 million

Capital Rx, Inc.: Raise no. 2, Dec 2020

Investors in this round

4 investors had bought by the notice of Jan 5, 2021: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$32 M of $53 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. J. Loiacono · Executive Officer, Director
  • Joseph J. Alexander · Executive Officer, Director
  • Laura J. Alemzadeh · Executive Officer · Secretary
  • Jared J. Kesselheim · Director
  • Kevin J. Hill · Director
  • Lenard J. Marcus · Director
  • Ryan J. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total offering amount consists of an initial closing of $31,960,627.84 and a milestone sale of $3,499,998.47 and up to an additional $17,539,367.40 at one or more subsequent closings with a right to purchase any remaining amount not sold.”

Signed by A.J. Loiacono, Ceo. Source: SEC Form D, newest notice filed Jan 5, 2021. Read the notice at the SEC.

equitySEC
Jul 2019$12 MNo. 1$10 to $50 million

Capital Rx, Inc.: Raise no. 1, Jul 2019

Investors in this round

1 investor had bought by the notice of Jul 19, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $16 M offered; $4 M still to sell
Smallest investment taken
$16,382,777
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A.J. Loiacono · Executive Officer, Director
  • Joseph Alexander · Director
  • Lenard Marcus · Director
  • Ryan Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total offering amount consists of $12,382,779.89 of equity securities and a warrant to purchase up to an additional $3,999,997.41 of equity securities.”

Signed by A.J. Loiacono, Ceo. Source: SEC Form D, newest notice filed Jul 19, 2019. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Capital Rx, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2025).

    SEC Form D · Sep 2025

  • The industry group it chose in its notices: Other.

    SEC Form D · Sep 2025

That is all the official record says: Capital Rx, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Capital Rx, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Capital Rx, Inc.
NameRoleNamed in
A. J. LoiaconoExecutive officerSep 2025
Joseph J. AlexanderExecutive officerJun 2022
Laleh J. AlemzadehSecretaryJun 2022
Laura J. AlemzadehSecretaryJan 2021
A.J. LoiaconoExecutive officerJul 2019
A. J. LoiaconoDirectorSep 2025
Daniel J. DelmastroDirectorSep 2025
Holly J. MaloneyDirectorSep 2025
Jared J. KesselheimDirectorSep 2025
Kevin J. HillDirectorSep 2025
Lenard J. MarcusDirectorSep 2025
Mark J. KandrysawtzDirectorSep 2025
Mostafa J. KamalDirectorSep 2025
Robert J. MittendorffDirectorSep 2025
Ryan J. KellyDirectorSep 2025
Feby J. AbrahamDirectorMar 2024
Joseph J. AlexanderDirectorJul 2021
A.J. LoiaconoDirectorJul 2019
Joseph AlexanderDirectorJul 2019
Lenard MarcusDirectorJul 2019
Ryan KellyDirectorJul 2019